Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9287084PMC
http://dx.doi.org/10.1111/dth.15383DOI Listing

Publication Analysis

Top Keywords

acrodermatitis continua
4
continua hallopeau
4
hallopeau treated
4
treated ixekizumab
4
ixekizumab case
4
case report
4
acrodermatitis
1
hallopeau
1
treated
1
ixekizumab
1

Similar Publications

Acrodermatitis continua of Hallopeau (ACH) is a rare aseptic pustular dermatosis for which clinical guidelines are lacking and treatment is largely based on case reports. Biologically targeted therapies offer new therapeutic ideas, with TNF antagonists such as adalimumab showing promising efficacy in both adults and children.The IL-17 and IL-23 axes play a key role in the pathogenesis of ACH, and anti-IL-17A and anti-IL-23 antibodies have shown therapeutic efficacy.

View Article and Find Full Text PDF

Acrodermatitis continua of Hallopeau (ACH) is a rare pustular psoriasis variant that presents as sterile pustules on the hands and feet with a relapsing course. This condition is not easily treated, but literature shows some cases are successfully controlled with biologics such as etanercept, adalimumab, secukinumab, and ustekinumab. Mixed connective tissue disease (MCTD) is a type of autoimmune disease and is rarely seen in the pediatric population.

View Article and Find Full Text PDF

Acrodermatitis continua of Hallopeau (ACH) is a rare inflammatory condition primarily affecting the fingers. It is characterized by painful paronychia with sterile pustules on an erythematous base around the nail folds and in the nail bed, which can progress to nail deformation and atrophy. In severe cases, resorptive osteolysis is a possible sequela.

View Article and Find Full Text PDF

A 62-year-old Chinese woman presented to the hospital for help with generalized pustular psoriasis (GPP) and acrodermatitis continua of Hallopeau (ACH). While conventional treatments failed to achieve significant improvement, the patient received two doses of spesolimab, and the effect was remarkable. No adverse reactions were observed in the follow-up period.

View Article and Find Full Text PDF